Corrigendum: JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516)

Anna Sophia McKenney, Allison N. Lau, Amritha Varshini Hanasoge Somasundara, Barbara Spitzer, Andrew M. Intlekofer, Jihae Ahn, Kaitlyn Shank, Franck T. Rapaport, Minal A. Patel, Efthymia Papalexi, Alan H. Shih, April Chiu, Elizaveta Freinkman, Esra A. Akbay, Mya Steadman, Raj Nagaraja, Katharine Yen, Julie Teruya-Feldstein, Kwok Kin Wong, Raajit RampalMatthew G. Vander Heiden, Craig B. Thompson, Ross L. Levine

Research output: Contribution to journalComment/debatepeer-review

4 Scopus citations

Fingerprint Dive into the research topics of 'Corrigendum: JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516)'. Together they form a unique fingerprint.

Medicine & Life Sciences